The Efficacy of Sentimag in Detection of Sentinel Node Biopsy

Breast Cancer Clinical Trial

— SMART  

Official title:

SMART Study: Sentimag Along With Routine Technique in Detection of Sentinel Node Biopsy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02739425
• Other study ID #: 2015SUR79
• Status: Completed
• Phase: N/A
• Start date: September 22, 2016
• Est. completion date: May 1, 2018

Study information

• Verified date: April 2019
• Source: The Royal Wolverhampton Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the Sentimag/Sienna+ System (Sentimag®) in clinical routine practice. On the one hand this allows evaluation of the equivalence of the two techniques. On the other hand this ensures that patients do not experience any possible disadvantages by participating. The hypothesis behind this evaluation is that Sentimag is as efficient as conventional sentinel node mapping.

The programme will compare the Sentimag® with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB.

Description:

Sentinel lymph node biopsy (SLNB) is now the standard technique used in breast cancer patients with a clinically and radiologically negative axilla. SLNB for breast cancer was introduced in the 1990s3 and it significantly reduces the morbidity associated with axillary node dissection (ALND) including lymphedema, seroma, numbness, wound infection, reduced shoulder motility, and chronic pain.2 The gold standard for sentinel node detection is the 'combined technique'; using both blue dye and radioisotope injection. After allowing both radioisotope and blue dye to localize in the lymphatic system, the clinician uses a 'gamma probe' (a handheld scintillation counter) to locate the SLNs. The blue dye assists in localisation post-incision, with lymph nodes that are blue and/or radioactive are judged as 'SLNs' and excised. Some centres use either radioisotope or blue dye alone. Although detection rates are lower, they can still reach satisfying values in experienced centres.

The use of radioisotope exposes patients and healthcare workers to radiation, is heavily controlled by legislation (both on the specific training for operators and subsequent disposal of surgical waste), and provides poor pre-operative imaging. As a result, many centres have stopped undertaking routine pre-operative lymphoscintigraphy. There is thus a clinical need to develop new techniques for detecting sentinel nodes without these drawbacks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: May 1, 2018
• Est. primary completion date: May 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with primary breast cancer scheduled for Sentinel node biopsy;

• Patients who are clinically and radiologically node negative;.

• Patients aged =18 years at time of consent

• Patients are able and willing to give informed consent

• Ability and willingness to undertake all scheduled visits and assessments

Exclusion Criteria:

• Patients who are currently Pregnantcy or lactatingon;

• Patients with metastatic cancer;

• Subject has a known hypersensitivity to blue dye;

• Patients with intolerance or hypersensitivity to iron oxide or dextran compounds;, or to Sienna+

• Patients who have iron overload disease;

• Patients who has a pacemaker or other implantable device in the chest wall or shoulder;

• Previous axilla surgery, or impaired lymphatic function

• Subject is deprived of liberty or under guardianship

• Subject is indicated or scheduled for post-operative MRI investigation of the breast

Related Conditions & MeSH terms

• Breast Cancer
• Sentinel Node

Intervention

Device:
• Sentimag Device
The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB

Locations

Country	Name	City	State
United Kingdom	The Royal Wolverhampton NHS Trust	Wolverhampton

Sponsors (2)

Lead Sponsor	Collaborator
The Royal Wolverhampton Hospitals NHS Trust	Sysmex Medical

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of successful sentinel node biopsies (SLNB, detection rate per patient) with either the magnetic or the standard technique		6 Months
Secondary	Detection rate per node		6 Months
Secondary	Malignancy rate: proportion of nodes and patients with a malignant result in the definite pathological analysis.		6 Months
Secondary	Concordance rate: proportion of successful labelling with the standard and new technique per patient and per node		6 Months
Secondary	Malignancy concordance: proportion of successful labelling with the standard and new technique per malignancy positive patients and nodes		6 Months